OTCM
KMSTF
Market cap22mUSD
Sep 30, Last price
5.06USD
Name
Kadimastem Ltd
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
45.14%
Rev. gr., 5y
-12.93%
Revenues
0k
Net income
-27m
L+120.39%
CFO
-3m
L-75.15%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Kadimastem Ltd, an Israeli biopharmaceutical company, focuses on pioneering regenerative medicine therapies that utilize cells originating from human embryonic stem cells, primarily targeting neurodegenerative disorders. Its developmental pipeline features AstroRx, a clinical-grade human astrocyte therapy presently undergoing Phase 1/2a clinical trials for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. Additionally, the company is developing IsletRx, a clinical-grade pancreatic islet cell therapy designed to treat diabetes. Founded in 2008, Kadimastem maintains its headquarters in Ness Ziona, Israel.
Valuation
Title ILS in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||